|
|
Podcast: Multidisciplinary Task Force and Position Statement: Mitigating Disease Burden and Health Care Disparities in Relapsed/Refractory Multiple Myeloma
STATEMENT OF NEED
With the complex and rapidly evolving treatment landscape of multiple myeloma, it is vital that clinicians not only understand factors for informing selection of current and emerging combination and sequential therapeutic strategies, but also employ interdisciplinary strategies for reducing disparities in relapsed/refractory multiple myeloma care. The development of novel therapeutic options has significantly improved treatment outcomes for patients with relapsed/refractor... |
|
|
Treating SCLC in the Relapsed/Refractory Setting: Giving Patients a Voice About Second-Line Therapy
SCLC is aggressive in nature with a high recurrence rate following initial treatment and a propensity to become resistant to conventional therapies. Early detection is critical, but many patients are diagnosed at an advanced stage where prognosis is poor. Progress in the second-line setting offers new hope for improving patient outcomes, but the rapid pace at which these advances are occurring present challenges for effectively integrating novel therapies into patient care. In fact, research s... |
|
|
HER3 in NSCLC " Navigating New Frontiers in Targeted Therapy
In patients with non-small cell lung cancer (NSCLC), human epidermal growth factor receptor 3 (HER3) is associated with both advanced disease and resistance to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)"directed therapies. Although there are therapeutic options targeting EGFR (HER1) and HER2, the potential of HER3 as an anti-cancer target has been largely overlooked. Overexpression of HER3 in most patients with NSCLC positions it as an appealing therapeutic targ... |
|
|
Advances in Recurrent/Metastatic Nasopharyngeal Carcinoma: Immunotherapy and Biomarkers
Target Audience
This activity was developed for medical oncologists, head and neck surgeons, radiation oncologists, physician associates, nurse practitioners, nurses and pharmacists involved in the care of patients diagnosed with metastatic nasopharyngeal carcinoma (NPC).
Program Overview
Greater understanding of the tumor microenvironment of nasopharyngeal carcinoma (NPC) has led to the introduction of immunotherapy into the NPC treatment landscape. Incorporating immunotherapy has change... |
|
|
Cracking the Code to Successful Stem Cell Mobilization in Multiple Myeloma
STATEMENT OF NEED
Multiple myeloma is the leading indication of autologous hematopoietic stem cell transplantation (ASCT) in hematologic malignancies, with high-dose therapy followed by ASCT representing a potentially curative treatment modality for eligible patients. Collecting peripheral blood stem cells (PBSCs) is an essential component of ASCT, and the collection of sufficient autologous PBSCs relies on the successful mobilization of hematopoietic stem cells from the bone marrow niche i... |
|
|
Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC.
Target Audience
The primary target audience for this activity are Academic and community-based physicians and team members, including hematologists, hematologic oncologists, medical oncologists, oncology nurses, NPs, PAs, and hematology-oncology pharmacists.
Statement of Need/Program Overview
Bispecific antibodies are relatively new agents in the treatment of multiple myeloma (MM). Because of this, many oncology clinicians are unfamiliar with their mechanism of action and the adverse even... |
|
|
Podcast: Multidisciplinary Task Force: Diagnosis and Management of Dedifferentiated Liposarcoma
STATEMENT OF NEED
Dedifferentiated liposarcoma (DDLPS) is an aggressive subtype of soft tissue sarcoma. Detection of MDM2 and/or CDK4 amplification distinguishes DDLPS from other types of undifferentiated sarcomas. Diagnosis of DDLPS remains challenging due to its complex karyotypes, quantitative genomic profiles, and pleomorphic pathological features (Nishio et al, 2021; Shen et al, 2022). Currently, surgical resection with or without radiation is the mainstay of treatment for localized di... |
|
|
Pathways to Precision: Integrating Genetic Counseling and Testing Into Cancer Care
STATEMENT OF NEED
Precision medicine is a cutting-edge approach that incorporates an individual’s genomic, environmental, and lifestyle information to deliver personalized healthcare. Genetic testing and counseling are crucial components of precision medicine, enabling clinicians to deliver the right care to the right patient at the right time (Turbitt et al, 2023). However, genetic testing often remains an untapped resource for patients who may benefit from genetic risk assessment and ca... |
|
|
What’s New With HER2: Charting New Paths in NSCLC Care - Module 1: HER2 in NSCLC: Actionable Insights and Testing Recommendations
STATEMENT OF NEED
With the identification of oncogenic drivers and the development of targeted therapies, comprehensive molecular assessment has become a cornerstone of non"small cell lung cancer (NSCLC) management. Human epidermal growth factor receptor 2 (HER2) alterations, which include gene mutations, gene amplifications, and protein overexpression, are emerging therapeutic targets. While testing can be used to guide treatment decisions, the heterogeneity of HER2 alterations and th... |
|
|
What’s New With HER2: Charting New Paths in NSCLC Care - Module 2: Current and Emerging Treatments for HER2-Mutated NSCLC
STATEMENT OF NEED
In recent years, the discovery of oncogenic drivers and development of targeted therapies have transformed the treatment of advanced non"small cell lung cancer (NSCLC). Alterations in human epidermal growth factor receptor 2 (HER2), which include gene mutations, gene amplifications, and protein overexpression, are therapeutic targets. Several HER2-targeted therapies are under investigation in NSCLC and have demonstrated clinical benefit, with trastuzumab deruxtecan re... |
|
|
Podcast: What’s New With HER2: Charting New Paths in NSCLC Care - Module 1: HER2 in NSCLC: Actionable Insights and Testing Recommendations
STATEMENT OF NEED
With the identification of oncogenic drivers and the development of targeted therapies, comprehensive molecular assessment has become a cornerstone of non"small cell lung cancer (NSCLC) management. Human epidermal growth factor receptor 2 (HER2) alterations, which include gene mutations, gene amplifications, and protein overexpression, are emerging therapeutic targets. While testing can be used to guide treatment decisions, the heterogeneity of HER2 alterations and th... |
|
|
Podcast: What’s New With HER2: Charting New Paths in NSCLC Care - Module 2: Current and Emerging Treatments for HER2-Mutated NSCLC
STATEMENT OF NEED
In recent years, the discovery of oncogenic drivers and development of targeted therapies have transformed the treatment of advanced non"small cell lung cancer (NSCLC). Alterations in human epidermal growth factor receptor 2 (HER2), which include gene mutations, gene amplifications, and protein overexpression, are therapeutic targets. Several HER2-targeted therapies are under investigation in NSCLC and have demonstrated clinical benefit, with trastuzumab deruxtecan re... |
|
|
Improving Equity in Endometrial Cancer Care and Treatment: Accelerating Change to Improve Patient Outcomes in Rural and Underserved Communities
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
In rural and underserved communities, disparities in incidence, treatment, and prognosis are pervasive among women with endometrial cancer. Key factors contributing to these gaps include limited access to oncology specialty care and lack of familiarity with current therapeut... |
|
|
Evolving Treatment Paradigms in HR+/HER2- Early Breast Cancer: Advancing Equitable Care in Rural and Underserved Communities
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
Hormone receptor"positive, human epidermal growth factor receptor 2"negative (HR+/HER2-) breast cancer accounts for up to 70% of all breast cancer cases. In recent years, therapies such as CDK4/6 inhibitors, PARP inhibitors, and novel endocrine therapies have been ... |
|
|
Targeting the PI3K/AKT/PTEN Pathway for Treatment of Breast Cancer: Innovative Solutions for Equitable Care
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
The PI3K/AKT/PTEN pathway has emerged as a key player in breast cancer development. Notably, up to 50% of patients with hormone receptor"positive, human epidermal growth factor receptor 2"negative (HR+/HER2-) breast cancer have actionable biomarkers within this pat... |
|
|
Advances in™ Beta-Thalassemia: The Evolving Therapeutic Landscape
Target Audience
This educational activity is directed toward hematologists and hematologist-oncologists, as well as pediatricians, nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with beta-thalassemia.
Program Overview
This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of β-thalassemia, with a forward-looking perspective on how new and novel agents might imp... |
|